Effects of melatonin on NO, MDA, GSH and NADPH expression in liver tissues of intrahepatic cholestasis rats

doi:10.12092/j.issn.1009-2501.2019.11.002

Abstract

Abstract:

AIM:To investigate the intervention of melatonin on rat intrahepatic cholestasis model and related mechanisms of oxidative stress interference. METHODS: Intraperitoneal injection of alpha-naphthylisothiocyanate was used to establish rat model of intrahepatic cholestasis, and melatonin was administered intragastrically. The biochemical indexes of liver function were detected and liver histopathology were observed and evaluated, the content of NO, MDA, GSH in liver homogenate was detected by TBA and microplate test, the expression of NADPH protein and mRNA in liver homogenate was detected by WES and RT-PCR.RESULTS:The results of biochemical detection of liver function in rat serum and observation of liver pathological sections showed that alpha-naphthylisothiocyanate could successfully reproduce the intraahepatic cholestasis rat model, and melatonin had an ideal intervention effect on the model. Compared with the normal group, the GSH of liver tissue in the model group was significantly lower than that in the normal group (P<0.05), the expression levels of NO and MDA increased significantly (P<0.01). After treatment with melatonin, GSH expression was significantly elevated in the liver tissue of the melatonin group as compared with the model group (P<0.05) while NO, MDA expression levels are significantly reduced (P<0.01). There was no significant difference in NADPH protein/mRNA expression levels in liver tissue of each group of rats (P>0.05).CONCLUSION:The effect of melatonin on intrahepatic cholestasis in rats is significant, which can effectively improve the oxidative stress status of rats with intrahepatic cholestasis. The anti-oxidative stress mechanism may be considered as one of the important mechanisms of melatonin intervention in the Intrahepatic cholestasis rat model, which has important significance for further research.

Key words: intrahepatic cholestasis, melatonin, NO, MDA, GSH, NADPH

CLC Number:

R575
R965.2

YU Han, ZHONG Xianggen, LI Yunzhou, XU Zongying, SHI Shaohua, DENG Xiulan. Effects of melatonin on NO, MDA, GSH and NADPH expression in liver tissues of intrahepatic cholestasis rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1221-1226.

References

［1］Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically［J］. J Hepatol, 2007, 46(3): 365-371.
［2］于乐成，陈成伟.胆汁淤积性肝病的诊治现状及研究方向［J］.临床肝胆病杂志,2019,35(2):241-246.
［3］张志荣, 张林林, 樊玉娟, 等. 中药多靶点治疗肝内胆汁淤积的研究进展［J］. 中药药理与临床, 2017, 33(1): 221-224.
［4］Hardeland R, Poeggeler B, Srinivasan V, et al. Melatonergic drugs in clinical practice［J］. Arzneimittelforschung, 2008, 58(1): 1-10.
［5］Ohta Y, Kongo-Nishimura M, Imai Y, et al. Melatonin attenuates disruption of serum cholesterol status in rats with a single alpha-naphthylisothiocyanate treatment［J］. J Pineal Res, 2007, 42(2): 159-165.
［6］Yu H,Li Y,Xu Z,et al.Identification of potential biomarkers in cholestasis and the therapeutic effect of melatonin by metabolomics,multivariate data and pathway analyses［J］.Int J Mol Med,2018,42(5):2515-2526.
［7］Li Y, Yu H, Xu Z, et al. Melatonin ameliorates ANIT induced cholestasis by activating Nrf2 through a PI3K/Aktdependent pathway in rats［J］. Mol Med Rep, 2019, 19(2): 1185-1193.
［8］Plaa GL, Priestly BG. Intrahepatic cholestasis induced by drugs and chemicals［J］. Pharmacol Rev, 1976, 28(3): 207-273.
［9］陈曦, 郭书文, 武建功, 等. 益气活血方对心肌梗死大鼠心肌细胞坏死与凋亡的影响［J］. 北京中医药大学学报, 2017, 40(8): 646-652.
［10］刘红杰, 李天昊, 詹莎, 等. 艾叶挥发油致小鼠急性肝毒性作用及其机制研究［J］. 中国临床药理学与治疗学, 2017, 22(3): 248-252.
［11］王艳红,冯铁新,蒲君峰,等.锰超氧化物歧化酶模拟物对四氯化碳致小鼠急性肝损伤的保护作用［J］.中国临床药理学与治疗学,2018,23(11):1209-1214.
［12］赵蕾,杨关根,刘智勇,等.养血活血汤对老年性便秘小鼠血清及结肠组织匀浆中NO、MDA、SOD、GSH的影响［J］.中华中医药学刊,2014,32(7):1708-1710.
［13］刘建国, 王宪, 陈明哲. 一氧化氮和细胞因子之间的相互调节作用［J］. 生理科学进展, 2000, 31(1): 63-66.
［14］Yin D. Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores［J］. Free Radic Biol Med, 1996, 21(6): 871-888.
［15］Armstrong JS, Jones DP. Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells［J］. FASEB J, 2002, 16(10): 1263-1265.
［16］Moreno-Sanchez R,Marin-Hernandez A,Gallardo-Perez JC,et al.Control of the NADPH supply and GSH recycling for oxidative stress management in hepatoma and liver mitochondria［J］.Biochim Biophys Acta Bioenerg,2018,doi:10.1016/j.bbabio.2018.07.008.
［17］Mejia SA,Gutman LaB,Camarillo CO,et al.Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD,NADPH/NADP(+) and GSH/GSSG ratios and reducing oxidative and inflammatory stress［J］. Eur J Pharmacol,2018,818:499-507.
［18］胥敏.褪黑素对脑缺血再灌注后脑组织中Nox2和Nox4表达影响的实验研究［D］.苏州大学,2014:19.

[1]	DU Caifeng, MAO Yunan, GAO Jia, WANG Juan, LI Xiaoye, TIAN Junsheng, LIU Hongqi. Research on serum metabolic markers of menopausal syndrome based on 1H-NMR metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 961-968.
[2]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[3]	WANG Jingang, LI Qiang, SUN Huiyan, WANG Hongquan. Recent progress in understanding the neuroprotective mechanism of carnosic acid in Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1073-1080.
[4]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[5]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[6]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[7]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[8]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[9]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[10]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[11]	ZHANG Wei, LIU Lei, GUAN Shaoyang, SHENG Zhao, SUN Wenwen. Analysis of the diagnostic value of fine-needle aspiration cytology and BRAF and RAS gene mutation screening for thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 653-657.
[12]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[13]	QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei. Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
[14]	WANG Juan, LIU Weiying, YE Yucai, FU Wenli, ZHANG Sha, LI Leping. Research progress of norepinephrine reuptake inhibitor combined with antimuscarinic in the treatment of obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 714-720.
[15]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.